Fly News Breaks for January 3, 2020
Jan 3, 2020 | 07:30 EDT
Oppenheimer analyst Jay Olson lowered his price target for Incyte to $96 from $100 after itacitinib failed to reach statistical significance on the primary endpoint of Day 28 ORR in the pivotal GRAVITAS-301 study. While itacitinib did improve the Day 28 ORR vs steroids alone, Olson tells investors in a research note that the numerical difference was not statistically significant and there was no benefit on the key secondary endpoint of six-month non-relapse mortality. The analyst maintains an Outperform rating and says he looks forward to 2020 catalysts including Phase 3 study results for rux cream in atopic dermatitis in Q1 and REACH3 in mid-2020.
News For INCY From the Last 2 Days
Feb 16, 2020 | 15:57 EST
Specialty Pharma Analyst Chen, Biotech Analysts Young & Merle, along with Key Opinion Leaders Dr. Goldberg, Skin Laser & Surgery Specialists of NY & NJ and Dr. Weinberg, Forest Hills Dermatology Group, discuss the competitive landscape in atopic dermatitis at a Group Luncheon Meeting being held at Cantor's New York offices on February 24 at 12 pm.